Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $3.72B |
| Revenue Growth (YOY): 10.65% |
| Profit (% of Rev): 93.85% |
| Income (% of Rev): 36.03% |
| Income Growth (YOY): 33.02% |
| Operating Income: $1.18B |
| Operating Cash Flow: $1.29B |
| Operating Cash Flow Growth (YoY): 15.88% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $37.44B |
| Total Liabilities: $8.12B |
| Cash & Equivalent: $2.01B |
| Total Debt: $2.70B |
| Debt/Equity: 0.09 |
| Quick Ratio: 4.46 |
| Current Ratio: 5.28 |
| Price/Book: 3.88 |
| Price/Earnings: 21.19 |
| EBITDA: $1.18B |
| EPS: 12.4 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.